Losses down, revenues up in Amrad half-years

By Melissa Trudinger
Thursday, 19 February, 2004

Amrad (ASX:AML) released its half-year results today, revealing a 10 per cent increase in revenues to AUD$8.14 million and a decrease in operating loss to $2.2 million -- down 48 per cent.

The results were helped along by receipt of the first milestone payment from Merck Sharp and Dohme in December, which boosted revenues by $4.2 million. The company has so far received $11.7 million out of a potential US$112 million plus royalties if asthma drugs based on the IL-13 receptor project are successfully commercialised.

CEO Peter Smith said additional milestone payments from the partnership would be received over the next few years.

At the end of December, Amrad had $60.6 million in the bank, slightly more than the $60 million it had at the end of the 2002-2003 financial year. The company is expecting to have a modest drawdown in capital over the remainder of the financial year.

"We are focusing on costs throughout the company and a key element of this is a streamlining of the R&D portfolio," Smith said. "Amrad now has a clear R&D strategy that plays to its strengths."

Shortly after Smith was named the company's new CEO last year, Amrad has outlined plans to spin out its virology projects into a separate entity. Smith said the name Avexa had been reserved for the new company, and a number of spin-out strategies were currently under evaluation.

Phase II clinical trials on Amrad's most advanced product, emfilermin, which is being tested as a treatment for infertility by partner Serono, are expected to be completed in the second half of calendar year 2004.

Related News

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Towards safer epilepsy treatment for pregnant women

New research conducted in organoids is expected to provide pregnant women with epilepsy safer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd